KINSHASA, 6 November 2026 — Two experimental vaccines designed specifically against Bundibugyo virus could join an ongoing clinical trial in the Democratic Republic of the Congo (DRC), after expert advisers convened by the World Health Organization (WHO) recommended that they undergo further evaluation during the current outbreak.
In a news release dated 4 November, WHO said its Technical Advisory Group on Candidate Vaccine Prioritization had recommended adding ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna’s mRNA-1469 to the Tumaini clinical trial. Both candidates were developed to protect against Bundibugyo virus, the Ebola virus species responsible for the current outbreak in the DRC.
The recommendation followed a review of available preclinical and early clinical evidence. The candidates will enter the DRC trial only after national approvals. They are investigational products, not licensed vaccines for Bundibugyo virus disease, and the recommendation does not establish that either vaccine prevents infection or severe illness.
A single trial is designed to assess multiple vaccine candidates
The Tumaini trial is led by the DRC’s Institut National de Recherche Biomédicale, with support from WHO, Africa CDC, the University of Antwerp, Epicentre, Médecins Sans Frontières and other research partners. Its platform design allows several vaccine candidates to be assessed under one trial framework rather than requiring a separate study for every product.
The trial uses ring vaccination. When a case is confirmed, researchers identify eligible contacts of the patient and contacts of those contacts, then invite them to participate in a defined vaccination ring. WHO reported that four rings were already in place when it announced the new recommendations, with additional rings being prepared.
The first vaccine being evaluated in Tumaini is Ervebo, which is licensed against Zaire ebolavirus. Its performance against Bundibugyo virus is being studied and should not be assumed from its approval for a different Ebola virus species. The new candidates are important because they were specifically designed for the virus involved in the present outbreak.
Treatment studies are also testing several investigational options
WHO said research into potential treatments is progressing alongside the vaccine trial. The WHO-sponsored PARTNERS study, launched in July, is evaluating whether the monoclonal antibody MBP134, the antiviral remdesivir or a combination of both can improve survival among patients with confirmed Bundibugyo virus disease. WHO also said maftivimab is expected to be added to the trial as another potential treatment.
A separate post-exposure prophylaxis study involving obeldesivir is also under way. These medicines remain under investigation. Their inclusion in a clinical study does not mean that their effectiveness against Bundibugyo disease has been established or that they are available as routine treatment.
WHO expects initial findings from the treatment studies in the coming months and results from the vaccine trial in early 2027. The timetable will depend on trial progress, recruitment, follow-up and the quality of evidence generated during the outbreak response.
Research does not replace immediate outbreak-control measures
The expansion of clinical research is a significant development, but vaccines under evaluation cannot replace the measures needed to protect communities now. Early detection, laboratory confirmation, contact tracing, timely supportive care, infection prevention and control, safe and dignified burials and trusted community engagement remain central to outbreak response.
For neighbouring countries, including those with travel and trade links to the DRC, the research reinforces the need for sustained surveillance and cross-border coordination. Health authorities should continue to assess exposure risks, strengthen laboratory readiness and communicate clearly about what is known, what remains under investigation and when new evidence becomes available.
The trial’s significance will ultimately be measured by evidence of safety and protection, not by the number of candidates announced. Until results are available and regulatory decisions are made, the two new vaccines should be described as experimental candidates being considered for clinical evaluation.
Sources and further reading
- WHO — Two new candidate vaccines to join Ebola trial as treatment research advances (4 November 2026)
- WHO — Expert recommendations on Bundibugyo candidate treatments and vaccines (28 May 2026)
- WHO — PARTNERS treatment trial opens patient enrolment in the DRC (2 July 2026)
- WHO — Ebola disease: outbreak information and research updates
- Institut National de Recherche Biomédicale, Democratic Republic of the Congo



